Announcement on Purchasing Liability Insurance for Directors and Senior Management
Securities code: 603717 Securities abbreviation: Tianyu Biotechnology Announcement number: 2026-050
Tianyu Biotechnology Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Tianyu Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held the 14th meeting of the fifth board of directors on June 29, 2026, and reviewed the "Proposal on Purchasing Liability Insurance for Directors and Senior Management Personnel". In order to improve the company's risk control system, ensure that the company's directors and senior managers can fully exercise their rights and perform their duties, and reduce corporate governance and operational risks, the company plans to purchase liability insurance (hereinafter referred to as "Dong Gao Liability Insurance") for the company and all directors and senior managers in accordance with the "Code of Governance for Listed Companies" and other relevant regulations. All directors of the company, as stakeholders, abstained from voting, and this proposal was directly submitted to the company's third extraordinary shareholders' meeting in 2026 for review. The specific situation is as follows:
1. Dong Gao Liability Insurance Plan
Insured person: Tianyu Biotechnology Co., Ltd.
Insured: the company and all directors and senior managers (specifically, the final signed insurance contract shall prevail)
Compensation limit: no more than RMB 50 million per year (specifically subject to the final signed insurance contract)
Insurance fee: no more than RMB 250,000 per year (specifically subject to the final signed insurance contract)
Insurance period: 12 months (the specific start and end time shall be subject to the final signed insurance contract, and the insurance can be renewed or re-insured on an annual basis)
In order to improve the efficiency of decision-making, the company's board of directors requested the shareholders' meeting to authorize the company's management to handle specific matters related to the purchase of Donggao liability insurance within the authority of the above plan (including but not limited to identifying other relevant responsible personnel; identifying insurance companies; determining the insurance amount, insurance premiums and other insurance terms; selecting and engaging insurance brokers or other intermediaries; signing relevant legal documents and handling other matters related to insurance, claims, etc.).
2. Review procedure
The company held the 14th meeting of the fifth board of directors on June 29, 2026, and reviewed the "Proposal on Purchasing Liability Insurance for Directors and Senior Management Personnel". All directors of the company, as stakeholders, abstained from voting. This proposal was submitted to the second meeting of the Remuneration and Appraisal Committee of the fifth session of the Board of Directors for review before being submitted to the Board of Directors, and all members abstained from voting. This proposal still needs to be submitted to the company’s third extraordinary shareholders’ meeting in 2026 for review.
Announcement is hereby made.
Board of Directors of Tianyu Biotechnology Co., Ltd.
June 30, 2026